Inhibiting NADPH Oxidases to Target Vascular and Other Pathologies: An Update on Recent Experimental and Clinical...

Area of Science:

• Biochemistry
• Molecular Biology
• Pathophysiology

Background:

• Reactive oxygen species (ROS) play dual roles in health and disease, acting as signaling molecules at low levels and causing damage at elevated concentrations.
• Dysregulated ROS production is linked to various pathologies, including endothelial dysfunction, cancer, and fibrosis, making ROS sources key targets for intervention.

Purpose of the Study:

• To review recent findings on NADPH oxidase (NOX) enzymes, crucial sources of ROS in cellular homeostasis and disease.
• To summarize clinical trials investigating the inhibition of NOX enzymes for treating pathologies such as diabetes, idiopathic pulmonary fibrosis (IPF), and primary biliary cholangitis (PBC).

Main Methods:

• Literature review of recent research on NOX enzyme functions and their roles in disease.
• Analysis of clinical trial data for therapies targeting NOX enzymes.

Main Results:

• Specific NOX enzymes (NOX1, NOX2, NOX4, NOX5) are implicated in distinct pathologies like hypertension, atherosclerosis, and ROS-induced ROS release (RIRR) signaling.
• NOX4-derived hydrogen peroxide can activate NOX2, leading to mitochondrial ROS release, highlighting complex ROS signaling pathways.

Conclusions:

• NOX enzymes represent promising therapeutic targets for a range of diseases.
• Inhibiting specific NOX isoforms offers potential clinical strategies for managing conditions including diabetes, IPF, and PBC.